Showing 3741-3750 of 5646 results for "".
- FDA Accepts Eluminex Biosciences' IND Application for Trispecific Fusion Antibody for DMEhttps://modernod.com/news/fda-accepts-eluminex-biosciences-ind-application-for-trispecific-fusion-antibody-for-dme/2482259/Eluminex Biosciences announced the acceptance of its EB-105 IND application to the FDA. EB-105 is a novel trispecific fusion antibody targeting VEGF-A (and isomers), VEGF-B, placental growth factor (PlGF), angiopoetin-2 (Ang-2), and interleukin-6 receptor (IL-6R) for the treatment of DM
- Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase 1/2 Trial Evaluating Gene Therapy for XLRShttps://modernod.com/news/atsena-therapeutics-announces-positive-clinical-data-from-the-first-cohort-of-phase-12-trial-evaluating-gene-therapy-for-xlrs/2482257/Atsena Therapeutics announced positive preliminary data from the first cohort of the ongoing LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201 utilizes AAV.SPR, the company’s novel sprea
- Heidelberg Engineering to Showcase New Imaging Technology at ARVOhttps://modernod.com/news/heidelberg-engineering-to-showcase-new-imaging-technology-at-arvo/2482254/At the upcoming ARVO meeting in Seattle, Heidelberg Engineering will showcase a wide range of imaging applications from basic vision research to clinical trials and guided therapy. SeeLuma For the first time, Heidelberg Engineering will demonstrate
- Qlaris Bio Completes $24 Million Series B Financing Round to Advance IOP-lowering Drug Candidate for Glaucomahttps://modernod.com/news/qlaris-bio-completes-24-million-series-b-financing-round-to-advance-iop-lowering-drug-candidate-for-glaucoma/2482252/Qlaris Bio announced it has closed a $24 million Series B financing round to support the continued clinical development of QLS‑111, a first-in-class therapeutic being developed to lower IOP by targeting episcleral venous pressure (EVP). Qlaris is currently conducting two US ph
- Iantrek Presents New Data for CycloPen System with AlloFlo Carriershttps://modernod.com/news/iantrek-presents-new-data-for-cyclopen-system-with-alloflo-carriers/2482249/At the ASCRS meeting in Boston, Iantrek presented new data for its micro-interventional glaucoma surgical device CycloPen with AlloFlo. CycloPen is Iantrek’s microinterventional system for the ab-interno construction, modification, reinforcement and repair of a cyclodialysis.
- Inflammasome Therapeutics Announces First Patient Dosed in Geographic Atrophy Clinical Trialhttps://modernod.com/news/inflammasome-therapeutics-announces-first-patient-dosed-in-geographic-atrophy-clinical-trial/2482248/Inflammasome Therapeutics announced the first patient has been dosed in a first-in-class clinical trial for a sustained release implant for geographic atrophy (GA) due to age-related macular degeneration (AMD). The phase 1 trial (ClinicalTrials.gov ID NCT06164587) is sponsored by the Univers
- Aldeyra Therapeutics Announces Planned Pivotal Clinical Trial for RP Drug Candidatehttps://modernod.com/news/aldeyra-therapeutics-announces-planned-pivotal-clinical-trial-for-retinitis-pigmentosa-drug-candidate/2482247/Aldeyra Therapeutics hosted the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City on April 25 where it presented recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.
- RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Wet AMD Treatmenthttps://modernod.com/news/revopsis-secures-165-million-seed-funding-to-advance-first-in-class-tri-specific-therapy-for-wet-amd-treatment/2482246/RevOpsis Therapeutics announced it has successfully closed its first seed funding round, raising $16.5 million to develop and commercialize treatments for chronic multifactorial diseases through the company's fully human multispecific proprietary Rev-Mod Platform. The 
- LEP Biomedical Closes Pre-Seed Funding to Advance HyaGuard Platformhttps://modernod.com/news/lep-biomedical-closes-pre-seed-funding-to-advance-hyaguard-platform/2482243/LEP Biomedical announced pre-seed funding of €100,000 ($107,000) over two 6-month periods, which the company says will allow for further preclinical milestones in the development of the HyaGuard platform. The funding was made through Enterprise Ireland. Accordin
- DigitalOptometrics Surpasses 2 Million Remote Eye Examshttps://modernod.com/news/digitaloptometrics-surpasses-2-million-remote-eye-exams/2482242/DigitalOptometrics announced it has surpassed 2 million remote comprehensive eye exams. DigitalOptometrics' remote eye exam platform is designed to allow optometrists to conduct comprehensive eye exams remotely, integrating video conferencing with remote operation of opht